睿知中国医院研究地图
候选清单

正在招募淋巴瘤I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由深圳大学总医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方深圳大学总医院Shenzhen University General Hospital深圳医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07508605,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically confirmed relapsed/refractory B-cell lymphoma according to the 2020 World Health Organization (WHO) classification;

    入选标准第 2 条

    CD20 expression on tumor cells confirmed by flow cytometry and/or immunohistochemistry;

    入选标准第 5 条

  3. New York Heart Association (NYHA) Class III or IV heart failure, or left ventricular ejection fraction (LVEF) <50% on echocardiography;

    入选标准第 16 条

  4. No antibody-based therapy within 2 weeks prior to cell therapy. Exclusion Criteria

    入选标准第 12 条

  5. ECOG performance status of 0-2;

    入选标准第 3 条

  6. Abnormal complete blood count meeting any of the following: WBC ≤1 × 10⁹/L, ANC ≤0.5 × 10⁹/L, ALC ≤0.5 × 10⁹/L, or PLT ≤25 × 10⁹/L;

    入选标准第 14 条

    Laboratory abnormalities including, but not limited to, any of the following: total serum bilirubin ≥1.5 mg/dL; ALT or AST >2.5 times the upper limit of normal; serum creatinine ≥2.0 mg/dL;

    入选标准第 15 条

  7. At least one measurable and evaluable lesion according to RECIST 1.1;

    入选标准第 10 条

  8. currently pregnant or breastfeeding;

    入选标准第 29 条

    planning to become pregnant during the study period; or

    入选标准第 30 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07508605,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Aged 18 to 75 years, regardless of sex;
  2. Histologically confirmed relapsed/refractory B-cell lymphoma according to the 2020 World Health Organization (WHO) classification;
  3. ECOG performance status of 0-2;
  4. Expected survival of at least 3 months;
  5. CD20 expression on tumor cells confirmed by flow cytometry and/or immunohistochemistry;
  6. Patients who are resistant/refractory to CD19 CAR-T cell therapy or have low CD19 expression;
  7. No severe cardiac, pulmonary, hepatic, or renal disease;
  8. Able to understand and willing to sign the informed consent form for this study;
  9. No contraindications to peripheral blood mononuclear cell collection/apheresis;
  10. At least one measurable and evaluable lesion according to RECIST 1.1;
  11. Must have previously received standard first-line and second-line therapy;
  12. No antibody-based therapy within 2 weeks prior to cell therapy. Exclusion Criteria
  13. History of allergy to any component of the cell product;
  14. Abnormal complete blood count meeting any of the following: WBC ≤1 × 10⁹/L, ANC ≤0.5 × 10⁹/L, ALC ≤0.5 × 10⁹/L, or PLT ≤25 × 10⁹/L;
  15. Laboratory abnormalities including, but not limited to, any of the following: total serum bilirubin ≥1.5 mg/dL; ALT or AST >2.5 times the upper limit of normal; serum creatinine ≥2.0 mg/dL;
  16. New York Heart Association (NYHA) Class III or IV heart failure, or left ventricular ejection fraction (LVEF) <50% on echocardiography;
  17. Abnormal pulmonary function, with oxygen saturation <92% on room air;
  18. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant severe cardiac disease within 12 months prior to enrollment;
  19. Grade 3 hypertension with poor blood pressure control despite medication;
  20. History of craniocerebral trauma, disturbance of consciousness, epilepsy, severe cerebral ischemia, or cerebral hemorrhagic disease;
  21. Presence of autoimmune disease, immunodeficiency, or other conditions requiring immunosuppressive therapy;
  22. Presence of uncontrolled active infection;
  23. Prior treatment with any CAR-T cell product or other genetically modified T-cell therapy;
  24. Receipt of a live vaccine within 4 weeks prior to enrollment;
  25. Positive for HIV, HBV, HCV, or TPPA/RPR, or HBV carrier status;
  26. History of alcohol abuse, drug abuse, or psychiatric illness;
  27. Participation in any other clinical study within 3 months prior to enrollment in this study;
  28. Female subjects meeting any of the following conditions:
  29. currently pregnant or breastfeeding;
  30. planning to become pregnant during the study period; or
  31. of childbearing potential and unwilling or unable to use effective contraception;
  32. Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study.

排除标准:Exclusion Criteria:

    引自 ClinicalTrials.gov, NCT07508605, 参与标准,读取于 2026年11月10日。

    这些信息从哪里来

    登记记录

    ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07508605,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

    疾病与医院

    本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

    没有收录的内容

    登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

    提出更正ClinicalTrials.gov NCT07508605